[go: up one dir, main page]

DE60315964D1 - Verbesserung der herstellung von endogenen gonadotropin - Google Patents

Verbesserung der herstellung von endogenen gonadotropin

Info

Publication number
DE60315964D1
DE60315964D1 DE60315964T DE60315964T DE60315964D1 DE 60315964 D1 DE60315964 D1 DE 60315964D1 DE 60315964 T DE60315964 T DE 60315964T DE 60315964 T DE60315964 T DE 60315964T DE 60315964 D1 DE60315964 D1 DE 60315964D1
Authority
DE
Germany
Prior art keywords
gonadotropine
endogenic
improvement
manufacture
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60315964T
Other languages
English (en)
Other versions
DE60315964T2 (de
Inventor
Rajneesh Taneja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Tap Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceuticals Inc filed Critical Tap Pharmaceuticals Inc
Publication of DE60315964D1 publication Critical patent/DE60315964D1/de
Application granted granted Critical
Publication of DE60315964T2 publication Critical patent/DE60315964T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60315964T 2002-03-28 2003-01-31 Verbesserung der herstellung von endogenen gonadotropin Expired - Fee Related DE60315964T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63197 1997-10-21
US10/063,197 US20030186892A1 (en) 2002-03-28 2002-03-28 Enhancement of endogenous gonadotropin production
PCT/US2003/003131 WO2003082319A1 (en) 2002-03-28 2003-01-31 Enhancement of endogenous gonadotropin production

Publications (2)

Publication Number Publication Date
DE60315964D1 true DE60315964D1 (de) 2007-10-11
DE60315964T2 DE60315964T2 (de) 2008-05-15

Family

ID=28452200

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315964T Expired - Fee Related DE60315964T2 (de) 2002-03-28 2003-01-31 Verbesserung der herstellung von endogenen gonadotropin

Country Status (9)

Country Link
US (1) US20030186892A1 (de)
EP (1) EP1490091B1 (de)
JP (1) JP2006502969A (de)
AT (1) ATE371462T1 (de)
CA (1) CA2480626A1 (de)
DE (1) DE60315964T2 (de)
ES (1) ES2292938T3 (de)
MX (1) MXPA04009455A (de)
WO (1) WO2003082319A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
RU2623206C2 (ru) 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2461818B1 (de) 2009-08-03 2018-10-17 Incube Labs, Llc Schluckbare kapsel und verfahren zur stimulation der inkretinproduktion im darmtrakt
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en) 2010-12-23 2014-07-01 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296A4 (de) 2018-07-20 2022-04-27 Lipocine Inc. Lebererkrankung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538948A (en) * 1987-01-30 1996-07-23 Novo Nordisk A/S Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone
DK272789D0 (da) * 1989-06-02 1989-06-02 Novo Nordisk As Fremgangsmaade og praeparat til behandling af infertilitet
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
EP0788799A3 (de) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagoniste für Behandlung von Fruchtbarkeitsstörungen
WO1998008533A1 (en) * 1996-08-30 1998-03-05 Peptech Limited Sustained peptide-release formulation
HU228736B1 (en) * 1998-04-23 2013-05-28 Zentaris Ivf Gmbh Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
WO2000027193A1 (en) * 1998-11-12 2000-05-18 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a gonadotropin releasing hormone analog

Also Published As

Publication number Publication date
EP1490091B1 (de) 2007-08-29
US20030186892A1 (en) 2003-10-02
EP1490091A1 (de) 2004-12-29
JP2006502969A (ja) 2006-01-26
ATE371462T1 (de) 2007-09-15
ES2292938T3 (es) 2008-03-16
MXPA04009455A (es) 2005-01-25
WO2003082319A1 (en) 2003-10-09
CA2480626A1 (en) 2003-10-09
DE60315964T2 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
ATE362770T1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE312635T1 (de) Ventilanordnung
EA200101089A1 (ru) Новый способ лечения
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ATE495187T1 (de) Dalda-analoge und ihre verwendung
DK1167354T3 (da) Racemisk huperzin A
GB0130677D0 (en) Medicaments and novel compounds
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE50212646D1 (de) Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung
SE9902597D0 (sv) New use
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
SE0301883D0 (sv) New use II
SE9303612D0 (sv) New use
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
SE0301885D0 (sv) New use IV

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee